Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 1.00 |
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379752 | 0.88 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL2058308 | 0.87 | FOLH1 (1.00) | FOLH1HPGD | |
| SCHEMBL4369851 | 0.86 | FOLH1 (0.77) | FOLH1MRGPRX4MEN1NPC1MITF | |
| SCHEMBL4368704 | 0.86 | FOLH1 (0.77) | FOLH1MRGPRX4SMN1; SMN2 | |
| SCHEMBL4373069 | 0.86 | FOLH1 (0.75) | FOLH1MRGPRX4MEN1NPC1MITF | |
| SCHEMBL13979858 | 0.83 | FOLH1 (0.71) | FOLH1MRGPRX4NPC1TP53XBP1 | |
| SCHEMBL4378845 | 0.83 | FOLH1 (0.71) | FOLH1MRGPRX4 | |
| SCHEMBL13954175 | 0.82 | FOLH1 (0.69) | FOLH1MRGPRX4MEN1NPC1MITF | |
| SCHEMBL4368048 | 0.82 | FOLH1 (0.69) | FOLH1MRGPRX4 | |
| SCHEMBL4379735 | 0.82 | FOLH1 (0.69) | FOLH1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | claimed |
| US-6740777-B2 | MERCAPTOALKYL BENZOIC ACID DERIVATIVE ARE USEFUL FOR INHIBITING NAALADASE (ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2004-05-25 | — | — | US | claimed |
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | EISAI INC. | 2003-05-29 | — | — | US | claimed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-7138543-B2 | Thiolalkyl benzoic acid derivatives | GUILFORD PHARMACEUTICALS INC. (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6740777-B2 | MERCAPTOALKYL BENZOIC ACID DERIVATIVE ARE USEFUL FOR INHIBITING NAALADASE (ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2004-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | NAALAD2, DNPEP, ALDH7A1 | FOLH1 14/4885MRGPRX4 2900/4885MEN1 3943/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885MRGPRX4 1296/4885MEN1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.